Selank nasal spray is the best-researched form of administration for this peptide. Almost all published studies in humans and animals using Selank have been based on nasal administration, making it the method of administration with the strongest scientific backing [1–4].
Developed in Russia, Selank is a synthetic peptide derived from the naturally occurring immunoregulatory peptide tuftsin. It has been specifically designed for intranasal administration, allowing for its absorption through the nasal mucosa, bypassing a significant portion of the degradation that occurs in the gastrointestinal tract [1,5].
If you want to learn more about the mechanisms of action, properties, and applications of this peptide, also read our main guide: https://bioevidencehub.com/peptyd-selank/.
What is Selank Nasal Spray?
Selank nasal spray contains a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). The peptide was developed by modifying tuftsin and adding a Pro-Gly-Pro fragment, which increases its stability and prolongs its biological activity [5,6].
Research suggests that Selank may affect several biological systems related to anxiety regulation, stress adaptation, mental resilience, cognitive functions, neuroplasticity, and the functioning of the immune system [1–4,7].
Because peptides are typically degraded in the gastrointestinal tract, nasal administration has become the preferred route of administration in both scientific research and clinical observations.
Why is Selank Administered Nasally?
Nasal administration represents a unique route of peptide delivery, as some compounds can reach the structures of the central nervous system more effectively than after oral administration.
Numerous studies on Selank have used the intranasal route when analysing anxiety-related behaviours, GABA receptor activity, BDNF regulation, neurotransmitter function, cognitive abilities, and immunomodulatory effects [1–4,7].
One of the key studies found that intranasal Selank affected the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus – a brain structure strongly linked to memory, learning, and neuroplasticity [3].
Does Selank Nasal Spray Work?
Current research suggests that Selank induces measurable biological effects in both laboratory and clinical settings.
Research has shown that Selank can modulate GABA receptor activity, inhibit enzymes responsible for enkephalin breakdown, influence the expression of genes related to neurotransmission and immune regulation, regulate BDNF expression, and exhibit an anxiolytic effect without significant sedative action [1,3,8,9].
Animal studies have consistently demonstrated a reduction in anxiety-related behaviours, while mechanistic studies indicate multiple pathways through which Selank may influence mood, cognitive function, and stress resilience [1,3,8].
While the results are promising, most of the available data comes from Russian clinical and preclinical studies. Larger international clinical trials are needed to more accurately assess efficacy, safety, and potential clinical applications.
Dosage of Selank Nasal Spray
Currently, there are no widely accepted dosing guidelines based on large international clinical trials.
Published studies have used different intranasal dosing regimens depending on the study objective [1–4].
In the peptide research field, the most frequently discussed daily ranges include:
| Typical range | Daily allowance |
|---|---|
| Low dose | 250–500 mcg |
| Moderate dose | 500–1000 mcg |
| Higher dose | 1000–2000 mcg |
It is worth remembering that these values arise mainly from observational protocols and clinical practice, rather than from official medical recommendations.
How to Use Selank Nasal Spray
Most published research utilising Selank has been based on intranasal administration.
General rules for using nasal sprays include gently clearing the nose before application, placing the applicator in one nostril, administering the correct amount of product, and repeating the process in the other nostril if required. It is usually advisable to avoid a strong inhalation directly after application to limit product run-off and increase its contact with the nasal mucous membrane.
Detailed instructions may vary depending on the concentration, formulation, and dispensing device used.
How quickly does Selank Nasal Spray work?
Most scientific research focuses on biological effects, rather than the subjective perceived time of action.
Research indicates that Selank may affect neurotransmitter systems, neuropeptide activity, and neurotrophic pathways relatively quickly after administration [1–3]. Some experiments have shown measurable neurobiological changes after only a short period of use, while long-term studies have described sustained anxiolytic effects after several weeks of administration [8].
However, the biological response can vary significantly depending on the study model, protocol, and individual biological factors.
Does Selank Nasal Spray Require Refrigeration?
Scientific publications rarely specify exact storage conditions as individual formulations may vary.
The stability of a peptide depends on many factors, such as concentration, the presence of preservatives, the composition of the solution, the manufacturing process, and whether the preparation has been previously dissolved.
Many peptide preparations are stored under refrigeration conditions to maintain stability, however, you should always follow the manufacturer's recommendations for the specific product.
How to Store Selank Nasal Spray
Storage recommendations depend on the manufacturer and formulation.
Typical practices include protecting the product from high temperatures, avoiding prolonged sun exposure, refrigerating if recommended, and avoiding multiple freeze-thaw cycles.
Manufacturer's instructions should always take precedence over general storage advice.
Opinions on Selank Nasal Spray – What Does Research Say?
Although individual experiences may vary, published studies most commonly describe effects related to reduced anxiety, improved stress resilience, enhanced emotional regulation, support for cognitive function, and minimal sedative effects compared to traditional anti-anxiety medications [1,8].
Research has also shown that Selank can enhance some of the anxiolytic effects of benzodiazepines, while simultaneously reducing some of their sedative actions and negative impact on motor coordination in animal models [10].
When assessing the potential properties of Selank, controlled scientific studies are of greater value than individual user reports.
Key Information
Selank nasal spray is the best-researched form of administration for this peptide. The majority of published human and animal studies have utilised the intranasal route, making it the most scientifically supported method.
Research suggests that Selank may affect anxiety, stress resistance, emotional regulation, cognitive functions, neuroplasticity, and the immune system through mechanisms related to GABA activity, enkephalin metabolism, BDNF regulation, and gene expression.
Despite the existence of frequently discussed dosage ranges, there are currently no universally accepted guidelines for use. Further large-scale clinical research is needed to better define efficacy, safety, optimal dosing strategies, and long-term effects.
Disclaimer
The content of this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, treatment, or dosing recommendations. Selank is not approved for all uses in many countries, and most available data comes from experimental, preclinical, or regional studies. Further large-scale clinical trials are necessary to confirm efficacy, safety, optimal dosing, and long-term effects.
For research purposes only: Selank products available from Semax Polska are intended solely for laboratory and scientific research. They are not intended for human consumption or for use in the diagnosis, treatment, prevention or alleviation of any diseases. Researchers should use these materials in accordance with applicable laws, regulations and standards governing scientific research.
References
[1] Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., & Myasoedov, N. F. (2018). Peptide-based anxiolytics: The molecular aspects of the heptapeptide Selank's biological activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642
[2] Behavioral Neurology Review. (2017). Neurobiological effects and therapeutic potential of Selank. Behavioral Neurology. https://onlinelibrary.wiley.com/doi/full/10.1155/2017/5091027
[3] Levitskaya, N. G., Andreeva, L. A., Nagaev, I. Y., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences, 431, 79–82. Available at: https://www.researchgate.net/profile/Natalia-Levitskaya/publication/23306196
[4] Letters to the Journal of Experimental and Clinical Pharmacology. Clinical investigations involving intranasal Selank. https://www.pismin.com/10.1134/S1062359019040071
[5] PubChem. (2026). Selank Compound Summary. National Centre for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/Selank
[6] Andreeva, L. A., Nagaev, I. Y., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Antiviral properties of structural fragments of the peptide Selank. Doklady Biological Sciences, 431(1), 79–82. https://doi.org/10.1134/S0012496610020031
[7] Zozulia, A. A., Neznamov, G. G., Syunyakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Y., Serebryakova, E. V., Siranchieva, O. A., Andryushenko, A. V., Telesheva, E. S., Syunyakov, S. A., Smulevich, A. B., Myasoedov, N. F., & Seredenin, S. B. (2008). [Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia]. Journal of Neurology and Psychiatry named after S.S. Korsakov, 108(4), 38–48. PMID: 18454096. https://pubmed.ncbi.nlm.nih.gov/18454096/
[8] Zozulya, A. A., Kost, N. V., Sokolov, O. Y., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. N., Zolotarev, Y. A., Ivanov, S. V., Andryushchenko, A. V., Myasoedov, N. F., & Smulevich, A. B. (2001). The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine, 131(4), 315–317. https://doi.org/10.1023/A:1017979514274
[9] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborskaya, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2014). Effect of tripeptide Pro-Gly-Pro on rat brain transcriptome in focal ischaemia. Molecular Biology, 48(2), 277–287. PMID: 25850296. https://pubmed.ncbi.nlm.nih.gov/25850296/
[10] Kost, N. V., Sokolov, O. Y., Zozulya, S. A., & Myasoedov, N. F. (2025). Combined action of benzodiazepine tranquilizers and peptide anxiolytic Selank in BALB/c mice. Neurochemical Journal, 19, 743–748. https://doi.org/10.1134/S1819712425700783